SCHEMBL1874346

SCHEMBL1874346

NC1CCN(c2ccc(-c3ccccc3)c(F)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.46
SSTR2 P30874 5/20 0.43
PDE7A Q13946 1/20 0.43
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42
SKP2 Q13309 1/20 0.42
PIM1 P11309 3/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.40
DPP4 P27487 2/20 0.38
KHK P50053 1/20 0.38
DPP7 Q9UHL4 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
IDO1 P14902 1/20 0.38
CYP2C19 P33261 1/20 0.38
TDO2 P48775 1/20 0.38
PDK2 Q15119 1/20 0.38
CALML3 P27482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18411537 0.83 PDK2 (0.46) MEN1ALDH1A1KMT2APDK2
SCHEMBL1704676 0.79 MEN1 (0.43) VCPPDE7APIM1MEN1ALDH1A1
SCHEMBL6650883 0.79 HTR7 (0.59) KHKPDK2
SCHEMBL3777705 0.78 SLC9A1 (0.39) PIM1MEN1ALDH1A1KMT2ACYP3A4
SCHEMBL4168468 0.75 LMNA (0.44) VCPPDE7AMEN1KMT2ADPP4
SCHEMBL931643 0.73 MBTD1 (0.57) VCPCKS1BSKP1SKP2MEN1
SCHEMBL4169516 0.72 SOS1 (0.46) MEN1ALDH1A1KMT2ADPP4
SCHEMBL24736690 0.72 HTR6 (0.41) VCPSSTR2PDE7APIM1KHK
SCHEMBL377788 0.72 KDM1A (0.48) DPP4
SCHEMBL30815824 0.72 KDM1A (0.48) DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939661-B2 Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis HOFFMAN-LA ROCHE INC. (US) 2011-05-10 US disclosed
US-20080064697-A1 PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES HOFFMAN-LA ROCHE INC. 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064697-A1 PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES SSTR5, SSTR3, NPY5R VCP 4258/4885SSTR2 8/4885PDE7A 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.